QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vaccinex-to-report-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer an...

 vaccinex-to-report-promising-new-clinical-data-revealing-pepinemabs-unique-mechanism-to-enhance-immunotherapy-at-aacr-in-chicago

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinica...

 vaccinex-faces-nasdaq-delisting-whats-going-on-with-the-stock

Vaccinex, Inc. (NASDAQ: VCNX) shares are trading lower after the company announced it received a delisting notification from Na...

 vaccinex-has-been-granted-australian-patent-number-2018237549-titled-treatment-of-cancer-with-a-semaphorin-4d-antibody-in-combination-with-an-epigenetic-modulating-agent

https://ipsearch.ipaustralia.gov.au/patents/2018237549

 vaccinex-reports-improved-immunity-correlating-with-clinical-benefit-of-pepinemab-combination-treatment-at-society-for-immunotherapy-of-cancers-annual-meeting

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer an...

 vaccinex-shares-resume-trade
Vaccinex Shares Resume Trade
10/31/2024 14:22:05

 vaccinex-reports-new-findings-for-signal-ad-phase-1b2-trial-of-pepinemab-at-clinical-trials-on-alzheimers-disease-conference-in-madrid-spain-reports-that-expression-of-plasma-gfap-and-pp-tau-217-biomarkers-appears-to-increase-predominantly-during-mci-and-that-this-is-inhibited-by-pepinemab-treatment

Vaccinex (NASDAQ:VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antib...

 whats-going-on-with-vaccinex-stock-wednesday

Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warran...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION